GET DAILY SIGNALSFractyl Health (GUTS) Shares Drop -85% in 30 Days on Study Data and Lawsuit Overhang
Key Takeaways
- Fractyl Health (GUTS) shares fell roughly 85% over the trailing 30 days, sliding from an adjusted close near $5.83 in late September to about $0.88.
- The decline accelerated on October 16, 2026, when the stock dropped more than 60% in a single session even after the company reported positive six-month results from its pivotal REMAIN-1 study of Revita.
- A securities class action filed the same day by multiple law firms — alleging overstated Revita efficacy and concealed trial-site issues — compounded the selloff and continues to weigh on sentiment.
- The second co-primary endpoint of REMAIN-1, the 12-month weight-maintenance measure, remains unread until the first quarter of 2027, leaving the pivotal result incomplete.
- A cash runway extending into early 2027, together with a going-concern disclosure, keeps financing and dilution risk in focus for the pre-revenue company.
Fractyl Health (GUTS) Company Background
Fractyl Health, Inc. is a clinical-stage metabolic therapeutics company headquartered in Burlington, Massachusetts. Its lead product candidate, Revita, is a one-time endoscopic procedure known as duodenal mucosal resurfacing (DMR) designed to help patients maintain weight loss after discontinuing GLP-1 therapies for obesity and type 2 diabetes. The company is also advancing Rejuva, an early-stage gene therapy platform targeting durable metabolic disease remission. Because GUTS generates no product revenue, its valuation is driven almost entirely by clinical data, regulatory milestones, and financing developments — making it a binary, catalyst-driven biotech investment followed closely for pivotal readouts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Stock Performance: The Last 30 Days and Quarter
Over the last 30 days, GUTS has fallen approximately 85%, declining from an adjusted close near $5.83 in late September to about $0.88 by late October. The collapse was concentrated in a single session on October 16, 2026, when the stock lost more than 60% of its value on unusually heavy volume. The broader three-month trend has been equally negative. After trading near $9 in late August, the shares drifted lower through September before capitulating in October, leaving the stock near the bottom of its 52-week range and sharply below its 52-week high. From what I see, this kind of move often reflects more than just the headline numbers.
Key Drivers Behind the Recent Selloff
The defining catalyst was the October 16 release of six-month topline data from the Pivotal Cohort of REMAIN-1, a 308-participant, randomized, double-blind, sham-controlled study of Revita. The company reported that the trial met its pre-specified six-month co-primary endpoint, with Revita-treated patients retaining roughly 80% of their GLP-1-driven weight loss compared with about 67% for the sham group (p=0.0023). Despite the statistically significant headline result, the stock sold off sharply for two key reasons. First, the pivotal study's second co-primary endpoint — the percentage of patients maintaining at least 5% of total body weight loss at 12 months, judged against an FDA performance goal — will not be reported until the first quarter of 2027. Investors treated the six-month readout as incomplete de-risking rather than confirmation. Second, multiple law firms filed a securities class action on the same day, alleging the company overstated Revita's efficacy and concealed operational issues at a trial site, with a class period covering January 13, 2025 through January 29, 2026. The litigation overhang, combined with a cash position of roughly $47.1 million as of June 30, 2026 and a going-concern disclosure pointing to runway into early 2027, intensified concerns about further dilution and financing risk. I’m watching this closely as the incomplete data leaves room for continued volatility.
Earlier Quarter Trends and Credibility Concerns
The quarterly downtrend reflects a credibility reset that has persisted since early 2026. On January 29, 2026, six-month data from the REMAIN-1 Midpoint Cohort showed a more modest treatment effect than earlier interim readouts had suggested, and the company acknowledged that an outlier trial site had contributed materially to the results. The stock plunged roughly 68% to 75% over two sessions, and Morgan Stanley downgraded the shares from Overweight to Equal-weight while cutting its price target from $8 to $2. Securities class actions followed, and management's guidance that cash would last only into early 2027 kept dilution risk front and center. Those unresolved concerns carried the stock lower through the third quarter and set the stage for October's collapse. One thing that stands out is how quickly sentiment shifted on these clinical and legal updates.
Looking Ahead: Key Catalysts for GUTS
The next major catalyst for Fractyl Health is the 12-month co-primary endpoint from the REMAIN-1 Pivotal Cohort, expected in the first quarter of 2027, which will determine whether Revita clears the FDA's weight-maintenance performance goal. Ahead of that readout, investors will monitor the company's planned De Novo marketing application submission in late 2026, the Category III CPT code that takes effect on January 1, 2027, and any updates to its cash position and financing plans. Litigation developments, analyst rating changes, and management commentary on going-concern status will also shape near-term sentiment. As a pre-revenue clinical-stage company, Fractyl remains highly sensitive to clinical, regulatory, and capital-market outcomes.
Exploring AI Tools for Biotech Analysis
In my view, supplementing traditional research with data-driven platforms can help surface patterns across volatile names like this one. Tickeron’s AI Trading Bots provide access to hundreds of automated strategies spanning thousands of tickers, with only the top-performing and most relevant bots highlighted for review. Each differs in strategy, timeframe, and performance metrics, allowing users to filter approaches that match their own objectives and risk tolerance. Traders interested in supplementing their own research with automated, rules-based insights can explore the page to see which strategies are currently gaining traction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GUTS's Stochastic Oscillator is sitting in oversold zone for 17 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +3.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where GUTS advanced for three days, in 104 of 123 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
GUTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GUTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for GUTS entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GUTS's P/B Ratio (-84.131) is slightly lower than the industry average of (2.974). P/E Ratio (-0.967) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. GUTS's P/S Ratio (10000.000) is very high in comparison to the industry average of (439.237).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. GUTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GUTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement